Status:
WITHDRAWN
Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis
Lead Sponsor:
Neurogen Brain and Spine Institute
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.
Eligibility Criteria
Inclusion
- Patients with the diagnosis of definite Motor Neuron Disease/amyotrophic lateral sclerosis.
- Age 18-80 years
Exclusion
- HIV/HBV/HCV
- Malignancies
- Bleeding tendencies
- Pneumonia
- Renal failure
- Severe liver dysfunction
- Severe anemia \[hb \< 8\]
- Any bone marrow disorder
- Space occupying lesion in brain
- Pregnancy and lactation
- Other acute medical conditions/infections such as respiratory infection and pyrexia
- left ventricular ejection fraction \< 25%
- Patient on artificial ventilatory support
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02242071
Start Date
December 1 2008
End Date
September 1 2016
Last Update
October 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurogen brain and spine institute
Navi Mumbai, Maharashtra, India, 400706